ADPT Earnings & Financial Statements
Adaptive Biotechnologies Corporation
$25.68
+$0.06(+0.23%)
58
Overall
40
Value
63
Tech
71
Quality
Market Cap
$4.09B
Volume
428.92K
52W Range
$12.00 - $30.74
Target Price
$28.31
ADPT earnings and financial statements: Adaptive Biotechnologies Corporation's income statement, balance sheet and cash flow statement, annual and quarterly.
ADPT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $276.98M | $178.96M | $170.28M | $185.31M | $154.34M |
| Cost of revenue | $71.36M | $72.08M | $75.55M | $57.91M | $49.30M |
| Operating income | -$57.12M | -$162.55M | -$227.03M | -$200.19M | -$208.97M |
| EBITDA | -$29.88M | -$128.71M | -$189.31M | -$175.23M | -$193.34M |
| Net income | -$59.50M | -$159.49M | -$225.25M | -$200.19M | -$207.28M |
| EPS (diluted) | $-0.39 | $-1.08 | $-1.56 | $-1.40 | $-1.48 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $512.74M | $539.38M | $661.13M | $856.62M | $923.31M |
| Total liabilities | $287.74M | $336.89M | $352.86M | $392.52M | $319.24M |
| Shareholders’ equity | $218.79M | $202.71M | $308.40M | $464.17M | $603.99M |
| Cash and equivalents | $70.50M | $47.92M | $65.06M | $90.03M | $139.06M |
| Long-term debt | $196.79M | $211.56M | $220.05M | $224.13M | $106.69M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$45.99M | -$95.21M | -$156.32M | -$183.94M | -$192.73M |
| Capital expenditure | -$2.96M | -$3.66M | -$10.70M | -$16.35M | -$61.75M |
| Free cash flow | -$48.95M | -$98.88M | -$167.02M | -$200.29M | -$254.47M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ADPT | $25.68 | +0.2% | 428.92K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Adaptive Biotechnologies Corporation Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW